With the aim of making a positive impact in society, Ferrer has started the extension of its phase III clinical trial ADORE (ALS trial with Daily ORal Edaravone), with FNP122… More >>

Amylyx announced an update on the ongoing review of its Marketing Authorisation Application (MAA) for AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine [also known as taurursodiol]) for the treatment of adults with… More >>

Dear ALS and FTD Communities, We are sharing this update to keep you informed of Wave Life Sciences’ FOCUS-C9 and FOCUS-C9 open label extension studies, which are Phase 1b/2a clinical… More >>

• FDA granted accelerated approval of QALSODY based on a reduction of neurofilament, a marker of neurodegeneration • Superoxide dismutase 1 (SOD1)-amyotrophic lateral sclerosis (ALS) is a devastating, uniformly fatal, and ultra-rare… More >>

Apellis announced that people living with ALS will discontinue investigational treatment with systemic pegcetacoplan in the open-label period of the MERIDIAN study. The decision was made following an unblinded review… More >>

Cytokinetics announces COURAGE-ALS met criteria for futility at second interim analysis Company Plans to Discontinue the Phase 3 Clinical Trial of Reldesemtiv After Data Monitoring Committee Found No Effect on… More >>

SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States Biogen announced today the outcome of the U.S. Food and Drug Administration’s (FDA)… More >>

Topline results expected in 2024 Amylyx Pharmaceuticals announced the completion of enrollment in PHOENIX, aglobal, 48-week, randomized, placebo-controlled Phase 3 clinical trial of AMX0035 (sodium phenylbutyrate and taurursodiol [also known… More >>